Non-Invasive Drug Delivery by Thermal Microporation

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43GM074342-01
Agency Tracking Number: GM074342
Amount: $100,660.00
Phase: Phase I
Program: SBIR
Awards Year: 2005
Solicitation Year: 2005
Solicitation Topic Code: N/A
Solicitation Number: PHS2005-2
Small Business Information
Altea Therapeutics Corporation, 2056 Weems Road, Tucker, GA, 30084
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 MICHAEL HATCH
 (678) 495-3111
 MHATCH@ALTEATHERAPEUTICS.COM
Business Contact
 MATTHIAS POHL
Phone: (678) 495-3108
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Founded in 1998, Altea Therapeutics is developing its PassPort(tm) transdermal drug delivery system to deliver proteins and peptides, small-molecule drugs, genes and vaccines from a skin patch, eliminating the need for invasive needle injection. This breakthrough technology, currently undergoing Phase 1 clinical trials for transdermal delivery of insulin and hydromorphone, revolutionizes the way in which medicines can be administered, increasing efficacy, safety, and compliance. Previous studies have demonstrated that a wide range of pharmaceutical compounds can be delivered through microporated skin, including small molecules (hydromorphone, morphine, lidocaine), peptides (parathyroid hormone, insulin), proteins (interferon alpha, erythropoietin), and even adenoviral vectors. Preliminary data has also shown that proteins (bovine serum albumin) delivered by thermal microporation can generate robust antibody responses in animal models. Finally, studies with several hundred human subjects to date have shown that the microporation process is essentially without sensation and has few or no adverse side effects. In this SBIR Phase I application, we propose to devise a dramatically miniaturized laboratory embodiment (proof-of-concept) of the Activator component of the PassPort system. This will enable the use of this state-of- the-art technology, by virtue of its miniaturization, outside of a medical office or treatment room. This work will require innovative electrical and medical device engineering to achieve the stated objectives. In vitro testing will then be used to confirm functional equivalency between the existing table top models and the miniaturized model. In Phase II we will further optimize the engineering aspects of the Activator and PassPort(tm) system for (i) manufacturability and (ii) ease-of-use including human-factor engineering.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government